ivim tirzepatide shortage FDA confirms is still over, gives compounders a grace period No more Tirz at IVIM

Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease

It is also seen in some areas of India

Weight loss results by month with clinical trial data Abstract percentages are hard to feel

Any hair-shedding reports should be considered in that broader context

PARABEN-FREE, SULFATE FREE, SILICONE FREE, MINERAL OIL FREE, PHTHALATES FREE, CRUELTY-FREE, VEGAN